Physician profile
Donald Watson
NPI 1053337535
$8,218.23
in general payments reported to CMS, 2019-2025
22 companies · $678 in 2025
The $678 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,337 · 2020: $888 · 2021: $1,102 · 2022: $564 · 2023: $1,067 · 2024: $1,583 · 2025: $678.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,327.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,326.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,785.25 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $1,358.26 | 2019-2025 | Wegovy, Ozempic |
| Janssen Pharmaceuticals, INC | $600.48 | 2019-2021 | |
| Abbvie INC. | $560.42 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Axsome Therapeutics, INC. | $474.10 | 2024-2025 | Auvelity |
| Lilly USA, LLC | $392.91 | 2019-2024 | Mounjaro |
| Novartis Pharmaceuticals Corporation | $283.84 | 2019 | |
| Genentech USA, INC. | $250.00 | 2019-2020 | |
| Alkermes, INC. | $196.81 | 2023-2024 | Lybalvi |
| Pfizer INC. | $174.69 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $137.17 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $125.00 | 2019 | |
| Ucb, INC. | $125.00 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2021 | |
| Allergan, INC. | $124.74 | 2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $100.00 | 2019 | |
| Glaxosmithkline, LLC. | $93.45 | 2024 | Arexvy |
| Exact Sciences Corporation | $88.74 | 2024 | Cologuard Collection Kit |
| Ironshore Pharmaceuticals INC. | $75.70 | 2019 | |
| Amgen INC. | $72.09 | 2021-2023 | Otezla, Repatha |
| Nevro Corp. | $41.24 | 2021 | |
| Sanofi-Aventis U.S. LLC | $33.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Watson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.